Literature DB >> 34904526

Elucidating the role of N440K mutation in SARS-CoV-2 spike - ACE-2 binding affinity and COVID-19 severity by virtual screening, molecular docking and dynamics approach.

Malathi Kullappan1, Usha Mary2, Jenifer M Ambrose1, Vishnu Priya Veeraraghavan3, Krishna Mohan Surapaneni1,4,5,6.   

Abstract

COVID-19 has become a public health concern around the world. The frequency of N440K variant was higher during the second wave in South India. The mutation was observed in the Receptor Binding Domain region (RBD) of the Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) spike (S) protein. The binding affinity of SARS-CoV-2-Angiotensin-Converting Enzyme-2 (ACE-2) plays a major role in the transmission and severity of the disease. To understand the binding affinity of the wild and mutant SARS-CoV-2 S with ACE2, molecular modeling studies were carried out. We discovered that the wild SARS-CoV-2 S RBD-ACE-2 complex has a high binding affinity and stability than that of the mutant. The N440K strain escapes from antibody neutralization, which might increase reinfection and decrease vaccine efficiency. To find a potential inhibitor against mutant N440K SARS-CoV-2, a virtual screening process was carried out and found ZINC169293961, ZINC409421825 and ZINC22060839 as the best binding energy compounds. Communicated by Ramaswamy H. Sarma.

Entities:  

Keywords:  COVID-19; SARS-CoV-2; binding energy; elbasvir analogues; maraviroc analogues; public health; simeprevir analogues

Year:  2021        PMID: 34904526     DOI: 10.1080/07391102.2021.2014973

Source DB:  PubMed          Journal:  J Biomol Struct Dyn        ISSN: 0739-1102


  4 in total

1.  Adsorption of a thione derivative on carbon, AlN, and BN nanotubes: a detailed DFT and MD investigation.

Authors:  Jamelah S Al-Otaibi; Muhammad Shabeer; Y Sheena Mary; Y Shyma Mary; Renjith Thomas
Journal:  J Mol Model       Date:  2022-06-06       Impact factor: 1.810

Review 2.  Methodology-Centered Review of Molecular Modeling, Simulation, and Prediction of SARS-CoV-2.

Authors:  Kaifu Gao; Rui Wang; Jiahui Chen; Limei Cheng; Jaclyn Frishcosy; Yuta Huzumi; Yuchi Qiu; Tom Schluckbier; Xiaoqi Wei; Guo-Wei Wei
Journal:  Chem Rev       Date:  2022-05-20       Impact factor: 72.087

Review 3.  SARS-CoV-2 Omicron variant: Immune escape and vaccine development.

Authors:  Danyi Ao; Tianxia Lan; Xuemei He; Jian Liu; Li Chen; Daniel T Baptista-Hon; Kang Zhang; Xiawei Wei
Journal:  MedComm (2020)       Date:  2022-03-16

4.  Isolation and Genomic Characterization of SARS-CoV-2 Omicron Variant Obtained from Human Clinical Specimens.

Authors:  Pragya D Yadav; Nivedita Gupta; Varsha Potdar; Sreelekshmy Mohandas; Rima R Sahay; Prasad Sarkale; Anita M Shete; Alpana Razdan; Deepak Y Patil; Dimpal A Nyayanit; Yash Joshi; Savita Patil; Triparna Majumdar; Hitesh Dighe; Bharti Malhotra; Jayanthi Shastri; Priya Abraham
Journal:  Viruses       Date:  2022-02-24       Impact factor: 5.048

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.